-
Advances in Cancer Treatment Beyond Immunotherapy - -
| Artigo | Autor(es) | Referência |
|---|---|---|
| Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. | Ravaud Alain, Motzer Robert J, Pandha Hardev S, George Daniel J, Pantuck Allan J, Patel Anup, Chang Yen-Hwa, Escudier Bernard, Donskov Frede, Magheli Ahmed, Carteni Giacomo, Laguerre Brigitte, Tomczak Piotr, Breza Jan, Gerletti Paola, Lechuga Mariajose, Lin Xun, Martini Jean-Francois, Ramaswamy Krishnan, Casey Michelle, Staehler Michael, Patard Jean-Jacques, | The New England journal of medicine. 2016 12; 375(12):2246-2254. |
| Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. | Haas Naomi B, Manola Judith, Uzzo Robert G, Flaherty Keith T, Wood Christopher G, Kane Christopher, Jewett Michael, Dutcher Janice P, Atkins Michael B, Pins Michael, Wilding George, Cella David, Wagner Lynne, Matin Surena, Kuzel Timothy M, Sexton Wade J, Wong Yu-Ning, Choueiri Toni K, Pili Roberto, Puzanov Igor, Kohli Manish, Stadler Walter, Carducci Michael, Coomes Robert, DiPaola Robert S | Lancet (London, England). 2016 May; 387(May):2008-16. doi: 10.1016/S0140-6736(16)00559-6. pii: S0140-6736(16)00559-6. |
| Adjuvant therapy in renal cell carcinoma-past, present, and future. | Janowitz Tobias, Welsh Sarah J, Zaki Kamarul, Mulders Peter, Eisen Tim | Seminars in oncology. 2013 Aug; 40(Aug):482-91. doi: 10.1053/j.seminoncol.2013.05.004. pii: S0093-7754(13)00079-1. |
| Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. | Shaw Alice T, Gandhi Leena, Gadgeel Shirish, Riely Gregory J, Cetnar Jeremy, West Howard, Camidge D Ross, Socinski Mark A, Chiappori Alberto, Mekhail Tarek, Chao Bo H, Borghaei Hossein, Gold Kathryn A, Zeaiter Ali, Bordogna Walter, Balas Bogdana, Puig Oscar, Henschel Volkmar, Ou Sai-Hong Ignatius, | The Lancet. Oncology. 2016 Feb; 17(Feb):234-242. doi: 10.1016/S1470-2045(15)00488-X. pii: S1470-2045(15)00488-X. |
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. | Choueiri Toni K, Escudier Bernard, Powles Thomas, Tannir Nizar M, Mainwaring Paul N, Rini Brian I, Hammers Hans J, Donskov Frede, Roth Bruce J, Peltola Katriina, Lee Jae Lyun, Heng Daniel Y C, Schmidinger Manuela, Agarwal Neeraj, Sternberg Cora N, McDermott David F, Aftab Dana T, Hessel Colin, Scheffold Christian, Schwab Gisela, Hutson Thomas E, Pal Sumanta, Motzer Robert J, | The Lancet. Oncology. 2016 Jul; 17(Jul):917-927. doi: 10.1016/S1470-2045(16)30107-3. pii: S1470-2045(16)30107-3. |
| Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. | Cristofanilli Massimo, Turner Nicholas C, Bondarenko Igor, Ro Jungsil, Im Seock-Ah, Masuda Norikazu, Colleoni Marco, DeMichele Angela, Loi Sherene, Verma Sunil, Iwata Hiroji, Harbeck Nadia, Zhang Ke, Theall Kathy Puyana, Jiang Yuqiu, Bartlett Cynthia Huang, Koehler Maria, Slamon Dennis | The Lancet. Oncology. 2016 Apr; 17(Apr):425-439. doi: 10.1016/S1470-2045(15)00613-0. pii: S1470-2045(15)00613-0. |
| Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. | Kantarjian Hagop M, DeAngelo Daniel J, Stelljes Matthias, Martinelli Giovanni, Liedtke Michaela, Stock Wendy, Gökbuget Nicola, O'Brien Susan, Wang Kongming, Wang Tao, Paccagnella M Luisa, Sleight Barbara, Vandendries Erik, Advani Anjali S | The New England journal of medicine. 2016 Aug; 375(Aug):740-53. doi: 10.1056/NEJMoa1509277. pii: . |